Arden Trust’s Viking Therapeutics VKTX Stock Holding History

Arden Trust’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,364	Closed	-$30K	–	730
2020 Q1	$30K	Buy	+6,364	New	+$39.1K	0.01%	513

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Arden Trust's VKTX Position: Q2 2020 in Review

Arden Trust sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 6,364 shares — an estimated $30K sold.

Arden Trust first reported a position in VKTX in Q1 2020 and held it in 1 quarter. The position peaked at $30K in Q1 2020. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

Arden Trust reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 6,364 Viking Therapeutics shares in Q2 2020, an estimated $30K.
Arden Trust first reported a position in Viking Therapeutics in Q1 2020 and held it in 1 quarter.
Arden Trust's Viking Therapeutics position peaked at $30K in Q1 2020.
138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.